← Human Trials & Peer-Reviewed Studies
Magnesium in the treatment of alcohol withdrawal syndrome: a multicenter randomized controlled trial.
Plain-language guide to PMID 37012631 (2023): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 37012631
- Journal
- Alcohol and alcoholism (Oxford, Oxfordshire)
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Airagnes G et al. (10 authors)
- DOI
- 10.1093/alcalc/agad021
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.
Alcohol withdrawal syndrome (AWS) is a frequent and potentially life-threatening condition experienced in alcohol use disorder.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults, both men and women.
Inpatients were recruited in six different centers if they had a baseline score higher than eight on the Revised Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar).
The treatment group and baseline score were introduced as covariables in an analysis of covariance.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and multicenter.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
More than one site took part, so the participants came from several places.
What Was Measured
PubMed files the paper under topics including Magnesium, Substance Withdrawal Syndrome, Alcoholism, Benzodiazepines and Diarrhea.
Author keywords: alcohol use disorder, alcohol withdrawal syndrome and randomized controlled trial.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2023 (Alcohol and alcoholism (Oxford, Oxfordshire)), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.